Journal
NEUROPSYCHOPHARMACOLOGY
Volume 39, Issue 1, Pages 220-229Publisher
NATURE PUBLISHING GROUP
DOI: 10.1038/npp.2013.181
Keywords
psychiatric genetics; animal models; stem cells
Categories
Ask authors/readers for more resources
Despite high prevalence and enormous unmet medical need, the pharmaceutical industry has recently de-emphasized neuropsychiatric disorders as 'too difficult' a challenge to warrant major investment. Here I describe major obstacles to drug discovery and development including a lack of new molecular targets, shortcomings of current animal models, and the lack of biomarkers for clinical trials. My major focus, however, is on new technologies and scientific approaches to neuropsychiatric disorders that give promise for revitalizing therapeutics and may thus answer industry's concerns.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available